PT-141 Dosage Chart.

There is no published human trial of subcutaneous PT-141 at these doses in men. The approval, and every dose on this page, comes from trials in premenopausal women with hypoactive sexual desire disorder. The male data that exists used the discontinued intranasal formulation: 10 mg intranasally in 342 men who had failed sildenafil produced positive clinical outcomes in 33.5% versus 8.5% on placebo. You cannot convert an intranasal milligram into a subcutaneous one; bioavailability differs enormously between the two routes, and 10 mg up the nose is not 10 mg into the abdomen. Men using this are extrapolating from a female indication and a different delivery route. That may still be a reasonable bet, but it is extrapolation rather than established dosing.

Because PT-141 is dosed in whole milligrams rather than the micrograms most research peptides use. 1.75 mg drawn from a 10 mg vial reconstituted with 2 mL works out to 0.35 mL, which reads as 35 units on a U-100 syringe. That is a normal PT-141 draw, not a decimal error. If the volume stings going in, reconstitute the same vial with 3 mL instead; the dose then reads about 52 units, more liquid but a gentler injection, and you will need a 1 mL barrel rather than a 0.5 mL one. Never change the water volume without redoing the arithmetic, because the unit number changes with it.

Technically the only hard interval on the label is one dose per 24 hours, so two consecutive days is not a violation. But consecutive-day dosing is exactly the pattern that produced focal hyperpigmentation in 38% of patients in the daily-dosing study, and the label explicitly names daily dosing as a risk factor alongside darker skin. Spacing your doses out costs you nothing; the skin changes may not reverse. Treat back-to-back days as something you do rarely and knowingly, not as your default.

The lyophilised powder is stable at room temperature provided it is kept dark and dry, and the commercial autoinjector is labelled for storage at or below 25 °C, protected from light and never frozen. Once you reconstitute, keep it at 2–8 °C in the fridge. Worth flagging honestly: refrigeration of reconstituted vials is standard peptide handling convention rather than something the FDA label addresses, because the approved product ships premixed and never passes through a powder stage in the user’s hands.

Nausea is the defining side effect of this compound, not a sign that you mixed it wrong or injected badly. It hit about 40% of trial participants at the standard dose, 13% used an antiemetic to manage it, and 8% left the trials because of it. The levers that genuinely help are eating lightly beforehand and dropping to 1.0–1.25 mg, accepting the weaker evidence at those doses. If nausea reliably shows up before any benefit does, that is not a problem to engineer around. It is a real answer about whether this compound suits you.

The only published co-administration study gave 7.5 mg intranasal PT-141 with 25 mg sildenafil to 19 men, measured erections with a RigiScan under visual stimulation rather than in real life, and reported no new adverse events versus either drug alone. That is a small, short, crossover study on a different route, so it does not establish safety for injected PT-141 plus a full PDE5 dose. Both compounds move blood pressure, and PT-141's own rise peaks at 2–4 hours. If you combine them, use low doses of each and actually measure your blood pressure rather than assuming the interaction is neutral.

Modestly, and the numbers are worth seeing before you spend money. Across the two phase 3 trials in 1,247 women, desire scores improved 0.35 points more than placebo and distress scores fell 0.33 points more, both statistically significant, with effect sizes of roughly 0.26 to 0.43. Around 58% met the responder definition against 36% on placebo, so roughly one additional responder for every five people treated, on top of a large placebo response. This is a genuine drug with a genuine effect, and it is not a light switch.

No, and any protocol that gives you one is describing a different compound. PT-141 is purely on-demand: half-life is about 2.7 hours and it is cleared mostly in urine, with nothing accumulating between doses. There is no loading period, no cycle, no taper and no off-week to observe beyond staying under 8 doses a month. A protocol telling you to run it daily for a few weeks to build levels is prescribing precisely the schedule that caused hyperpigmentation in the label’s own daily-dosing study.